MET and neoplasm: Key components of the TGF-β and of MET signaling pathways are downmodulated in ULMs (Figure 5B and Table 4), both having a role in cell growth control, tumor progression, and oncogenic effects associated with invasive growth and extracellular matrix remodeling [44], [46].